Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience.
Fiche publication
Date publication
juin 2017
Journal
Inflammatory bowel diseases
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Olivera P, Thiriet L, Luc A, Baumann C, Danese S, Peyrin-Biroulet L
Lien Pubmed
Résumé
Infliximab (IFX) and adalimumab (ADA) are widely used in the treatment of patients with Crohn's disease (CD). There are few published data on the treatment persistence of IFX and ADA in patients with CD.
Mots clés
Adalimumab, administration & dosage, Adult, Certolizumab Pegol, administration & dosage, Crohn Disease, drug therapy, Female, Follow-Up Studies, France, Humans, Infliximab, administration & dosage, Male, Medication Adherence, statistics & numerical data, Multivariate Analysis, Retrospective Studies, Treatment Outcome, Tumor Necrosis Factor-alpha, antagonists & inhibitors, Young Adult
Référence
Inflamm. Bowel Dis.. 2017 06;23(6):976-985